Effect of a combined oral contraceptive containing 20 μg ethinyl estradiol and 75 μg gestodene on hemostatic parameters

Gynecological Endocrinology

Volumn 22, Issue 1, 2006, Pages 1-4

  Aldrighi, José Mendes ^a,d   Carneiro De Campos, Luis Salvoni ^a   Eluf Gebara, Otávio Celso ^b   Petta, Carlos Alberto ^c   Bahamondes, Luis ^c  

^a Ponce School of Medicine   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF CAMPINAS   (Brazil)

^d NONE   (Brazil)

Author keywords

Combined oral hormonal contraceptives; Hemostasis; Prothrombotic risk

Indexed keywords

ANTITHROMBIN III; D DIMER; ETHINYLESTRADIOL; FEMIANE; FIBRINOGEN; GESTODENE; ORAL CONTRACEPTIVE AGENT; PROTEIN C; PROTEIN S; PROTHROMBIN;

ADULT; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE MARKER; DOSE RESPONSE; DRUG EFFECT; FEMALE; HEMOSTASIS; HUMAN; LABORATORY TEST; NORMAL HUMAN; ORAL CONTRACEPTION; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RISK FACTOR; THROMBIN TIME; THROMBOCYTE COUNT; THROMBOEMBOLISM;

ADOLESCENT; ADULT; BLOOD COAGULATION TESTS; CONTRACEPTIVES, ORAL, COMBINED; ETHINYL ESTRADIOL; FEMALE; HEMOSTASIS; HUMANS; NORPREGNENES; RISK FACTORS; THROMBOSIS;

EID: 33644817742     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590500430328     Document Type: Article

References (37)

1. Inman WMW, Vessey MP, Westerholm B, Engelund A. Thromboembolic disease and steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs. Br Med J 1970;2:203-209.
2. Kay CR. The Royal College of General Practitioners' Oral Contraception Study: some recent observations. Clin Obstet Gynaecol 1984;11:759-786.
3. Meade TW, Greenberg G, Thompson SG. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50 and 30 μg oestrogen preparations. Br Med J 1980;280:1157-1161.
4. Vessey MP, Mann JI, Meade TW. Thrombosis and oral contraception. Br J Hosp Med 1981;25:205-206.
5. Suissa S, Spitzer WO, Rainville B, Cusson J, Lewis M, Heinemann L. Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. Hum Reprod 2000;15:817-821.
6. Norris LA, Bonnar J. Haemostatic changes and the oral contraceptive pill. Baillieres Clin Obstet Gynaecol 1997;11:545-564.
7. Conard J. Biological coagulation findings in third-generation oral contraceptives. Hum Reprod Update 1999;5:672-680.
8. Prasad RN, Koh SC, Viegas OA, Ratnam SS. Effects on hemostasis after two-year use of low dose combined oral contraceptives with gestodene or levonorgestrel. Clin Appl Thromb Hemost 1999;5:60-70.
9. Jung-Hoffmann C, Kuhl H. Interaction with the pharmacokinetics of ethinylestradiol and progestogens contained in oral contraceptives. Contraception 1989;40:299-312.
10. Van der Mooren MJ, Klipping C, van Aken B, Helmerhorst E, Spielmann D, Kluft C. A comparative study of the effects of gestodene 60 μg/ ethinylestradiol 15 μg and desogestrel 150 μg/ethinylestradiol 20 μg on hemostatic balance, blood lipid levels and carbohydrate metabolism. Eur J Contracept Reprod Health Care 1999;4(Suppl 2):27-35.
11. Schindler AE. Differential effects of progestins on hemostasis. Maturitas 2003;46(Suppl 1):S31-S37.
12. Petersen KR, Sidelman J, Skouby SO, Jespersen J. Effects of monophasic low-dose oral contraceptives on fibrin formation and resolution in young women. Am J Obstet Gynecol 1993;168:32-38.
13. Fruzzetti F, Ricci C, Fioretti P. Hemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives. Contraception 1994;49:579-592.
14. Winkler UH, Schindler AE, Endrikat J, Dusterberg B. A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 μg and 30 μg ethinylestradiol. Contraception 1996;53:75-84.
15. Endrikat J, Klipping C, Gerlinger C, Ruebig A, Schmidt W, Holler T, Dusterberg B. A double-blind comparative study of the effects of a 23-day oral contraceptive regimen with 20 μg ethinyl estradiol and 75 μg gestodene and a 21-day regimen with 30 μg ethinyl estradiol and 75 μg gestodene on hemostatic variables, lipids, and carbohydrate metabolism. Contraception 2001;64:235-41.
16. The Oral Contraceptive and Hemostasis Study Group. The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. Contraception 2003;67:173-185.
17. Ferreira AC, Montes MB, Franceschini SA, Toloi MR. Third-generation progestogen type influences hemostatic changes caused by oral contraceptives in Brazilian women. Contraception 2001;64:353-356.
18. World Health Organization, Reproductive Health and Research. Improving access to quality care in family planning. Medical eligibility criteria for contraceptive use. 2nd ed. Geneva: World Health Organization, 2000.
19. Odegard OR, Lie M, Abildgarrd U. Heparin cofactor activity measured with an amidolytic method. Thromb Res 1975;6:287-294.
20. Jespersen J. Pathophysiology and clinical aspects of fibrionolysis and inhibition of coagulation. Dan Med Bull 1988;35:1-25.
21. Jespersen J, Petersen KR, Skouby ISO. Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid. Am J Obstet Gynecol 1990;163:396-403.
22. Speroff L, DeCherney A. Evaluation of a new generation of oral contraceptives. The Advisory Board for the New Progestins. Obstet Gynecol 1993;81:1034-1047.
23. Realini JP, Goldzieher JW. Oral contraceptives and cardiovascular disease: a critique of the epidemiologic studies. Am J Obstet Gynecol 1985;152:729-798.
24. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;346:1582-1587.
25. Fruzzetti F. Hemostatic effects of smoking and oral contraceptive use. Am J Obstet Gynecol 1999;180:S369-S374.
26. Petersen KR. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus. Dan Med Bull 2002;49:43-60.
27. Omsjo IH, Oian P, Maltauu JM, Osterud B. Effects of two triphasic oral contraceptives containing ethinylestradiol plus levonorgestrel or gestodene on blood coagulation in fibrinolysis. Acta Obstet Gynecol Scand 1989;68:27-30.
28. Notelovitz M, Kitchens CS, Khan FY. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: controlled comparative 12-month clinical trial. Am J Obstet Gynecol 1992;167:255-261.
29. Fruzzetti F, Ricci C, Nicoletti I, Fioretti P. Clinical and metabolic effects of a triphasic pill containing gestodene. Contraception 1992;46:335-347.
30. Siegbahn A, Ruusuvaara L. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers. Thromb Haemost 1988;60:361-364.
31. Abbate R, Pinto S, Rostagno C, Bruni V, Rosati D, Mariani G. Effects of long-term gestodene-containing oral contraceptive administration on hemostasis. Am J Obstet Gynecol 1990;163:424-429.
32. Alving BM, Comp PC. Recent advances in understanding clotting and evaluating patients with recurrent thrombosis. Am J Obstet Gynecol 1992;167:1184-1191.
33. Smirova S, Chochola M, Varejka P, Aschermann M. Thromboembolic complications in the use of oral estrogengestagen contraceptives. Vnitr Lek 2001;47:460-464.
34. Girolami A, Spiezia L, Rossi F, Zanon E. Oral contraceptives and venous thromboembolism: which are the safest preparations available? Clin Appl Thromb Hemost 2002;8:157-162.
35. Skouby SO, Jespersen J, Petersen KP. Metabolic effects of oral contraceptives. Adv Contracept 1993;9(Suppl 1):49-58.
36. Schindler AE. Differential effects of progestins on hemostasis. Maturitas 2003;46(Suppl 1):S31-S37.
37. Shoupe D. New progestins - clinical experiences: gestodene. Am J Obstet Gynecol 1994;170:1562-1568.